BIOMAT Database Logo BIOMAT Database Logo

[Loss of heterozygosity on chromosome 3p in breast cancer and precancerous lesion]. 2006

Xuan-li Tang, and Gen-you Yao, and Li-rong Chen, and Ze-ran Yang, and Shi-lan Li
Department of Pathology, Zhejiang University School of Medical, Hangzhou 310031, China.

OBJECTIVE To study the loss of heterozygosity (LOH) on chromosome 3p in breast cancers and precancerous lesion. METHODS LOH at 11 microsatellite loci was detected in 41 cases of breast cancers and 12 cases of precancerous lesion by polymerase chain reaction and silver stain. The expressions of ER, PR, FHIT and hMLH1 were detected in breast cancer by immunohistochemistry. RESULTS LOH on 3p was detected in 97% of breast cancers. D3S1295, D3S1029 and D3S1038 located at 3p14, 3p21-p22 and 3p25 were identified as the loci with most frequent LOH (53.1%, 43.6% and 52.5%). LOH of D3S1038 and expression of hMLH1 protein correlated with several clinicopathological features. LOH of D3S1295 had significant negative correlation with the expression of FHIT. In breast precancerous lesions, LOH on 3p was detected in 41.7% lesions. D3S1295 and D3S1029 were also identified as the most frequent LOH locus (27.3% and 16.7%). The smallest common LOH region seems likely lie between 3p14 and 3p25. CONCLUSIONS The smallest LOH region indicates the existence of breast tumor related genes and some of them affect gene expression.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D011230 Precancerous Conditions Pathological conditions that tend eventually to become malignant. Preneoplastic Conditions,Condition, Preneoplastic,Conditions, Preneoplastic,Preneoplastic Condition,Condition, Precancerous,Conditions, Precancerous,Precancerous Condition
D011960 Receptors, Estrogen Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important. Estrogen Receptor,Estrogen Receptors,Estrogen Nuclear Receptor,Estrogen Receptor Type I,Estrogen Receptor Type II,Estrogen Receptors Type I,Estrogen Receptors Type II,Receptor, Estrogen Nuclear,Receptors, Estrogen, Type I,Receptors, Estrogen, Type II,Nuclear Receptor, Estrogen,Receptor, Estrogen
D011980 Receptors, Progesterone Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives. Progesterone Receptors,Progestin Receptor,Progestin Receptors,Receptor, Progesterone,Receptors, Progestin,Progesterone Receptor,Receptor, Progestin
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002893 Chromosomes, Human, Pair 3 A specific pair of human chromosomes in group A (CHROMOSOMES, HUMAN, 1-3) of the human chromosome classification. Chromosome 3
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Xuan-li Tang, and Gen-you Yao, and Li-rong Chen, and Ze-ran Yang, and Shi-lan Li
Loss of heterozygosity on chromosome 7q31 in breast cancer.
May 1993, Lancet (London, England),
Xuan-li Tang, and Gen-you Yao, and Li-rong Chen, and Ze-ran Yang, and Shi-lan Li
[Loss of heterozygosity on chromosome 3p in thyroid tumors].
May 2008, Zhonghua bing li xue za zhi = Chinese journal of pathology,
Xuan-li Tang, and Gen-you Yao, and Li-rong Chen, and Ze-ran Yang, and Shi-lan Li
Differential loss of heterozygosity profile on chromosome 3p in ductal and lobular breast carcinomas.
October 2012, Human pathology,
Xuan-li Tang, and Gen-you Yao, and Li-rong Chen, and Ze-ran Yang, and Shi-lan Li
Loss of heterozygosity, chromosome 7q, and breast cancer.
June 1992, Lancet (London, England),
Xuan-li Tang, and Gen-you Yao, and Li-rong Chen, and Ze-ran Yang, and Shi-lan Li
Loss of heterozygosity on chromosome 11 q in breast cancer.
May 1995, Journal of clinical pathology,
Xuan-li Tang, and Gen-you Yao, and Li-rong Chen, and Ze-ran Yang, and Shi-lan Li
Loss of heterozygosity on chromosome 1q in human breast cancer.
September 1989, Proceedings of the National Academy of Sciences of the United States of America,
Xuan-li Tang, and Gen-you Yao, and Li-rong Chen, and Ze-ran Yang, and Shi-lan Li
Loss of heterozygosity on chromosome arm 3p in nasopharyngeal carcinoma.
October 1996, Genes, chromosomes & cancer,
Xuan-li Tang, and Gen-you Yao, and Li-rong Chen, and Ze-ran Yang, and Shi-lan Li
Loss of heterozygosity at chromosome 3p in epithelial ovarian cancer in China.
January 2002, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,
Xuan-li Tang, and Gen-you Yao, and Li-rong Chen, and Ze-ran Yang, and Shi-lan Li
Loss of heterozygosity on chromosome 7q and aggressive primary breast cancer.
January 1992, Lancet (London, England),
Xuan-li Tang, and Gen-you Yao, and Li-rong Chen, and Ze-ran Yang, and Shi-lan Li
Multiple sites of loss of heterozygosity on chromosome arms 3p and 3q in human breast carcinomas.
March 1996, Oncology reports,
Copied contents to your clipboard!